These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 31239074)
41. Adrenal and extra-adrenal nonfunctioning composite pheochromocytoma/paraganglioma with immunohistochemical ectopic hormone expression: comparison of two cases. Gong J; Wang X; Chen X; Chen N; Huang R; Lu C; Chen D; Zeng H; Zhou Q Urol Int; 2010; 85(3):368-72. PubMed ID: 20829582 [TBL] [Abstract][Full Text] [Related]
42. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas. Turchini J; Gill AJ Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631 [No Abstract] [Full Text] [Related]
43. Familial pheochromocytomas and paragangliomas. King KS; Pacak K Mol Cell Endocrinol; 2014 Apr; 386(1-2):92-100. PubMed ID: 23933153 [TBL] [Abstract][Full Text] [Related]
44. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Roman-Gonzalez A; Zhou S; Ayala-Ramirez M; Shen C; Waguespack SG; Habra MA; Karam JA; Perrier N; Wood CG; Jimenez C Ann Surg; 2018 Jul; 268(1):172-178. PubMed ID: 28257320 [TBL] [Abstract][Full Text] [Related]
45. Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/paraganglioma: long-term follow-up of 303 patients. Raber W; Schendl R; Arikan M; Scheuba A; Mazal P; Stadlmann V; Lehner R; Zeitlhofer P; Baumgartner-Parzer S; Gabler C; Esterbauer H Front Endocrinol (Lausanne); 2024; 15():1419028. PubMed ID: 39234504 [TBL] [Abstract][Full Text] [Related]
46. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968 [TBL] [Abstract][Full Text] [Related]
47. Clinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma. Cascón A; Robledo M Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189141. PubMed ID: 38908536 [TBL] [Abstract][Full Text] [Related]
48. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Garcia-Carbonero R; Matute Teresa F; Mercader-Cidoncha E; Mitjavila-Casanovas M; Robledo M; Tena I; Alvarez-Escola C; Arístegui M; Bella-Cueto MR; Ferrer-Albiach C; Hanzu FA Clin Transl Oncol; 2021 Oct; 23(10):1995-2019. PubMed ID: 33959901 [TBL] [Abstract][Full Text] [Related]
49. The phenotype of Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599 [TBL] [Abstract][Full Text] [Related]
51. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221 [TBL] [Abstract][Full Text] [Related]
52. [Pheochromocytoma and paraganglioma: basics for the general practitioner]. Loosli N; Köhler BB; Pechère-Bertschi A; Karenovics W; Triponex F Rev Med Suisse; 2014 Sep; 10(441):1650-2, 1654-5. PubMed ID: 25322623 [TBL] [Abstract][Full Text] [Related]
53. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453 [TBL] [Abstract][Full Text] [Related]
54. DNA flow cytometry in pheochromocytoma and paraganglioma. Jung WH; Yang WI; Park C; Choi IJ Yonsei Med J; 1992 Sep; 33(3):249-57. PubMed ID: 1292249 [TBL] [Abstract][Full Text] [Related]
55. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes. Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393 [TBL] [Abstract][Full Text] [Related]
56. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas. Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508 [TBL] [Abstract][Full Text] [Related]
57. Genomic Landscape of Pheochromocytoma and Paraganglioma. Jochmanova I; Pacak K Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423 [TBL] [Abstract][Full Text] [Related]
58. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434 [TBL] [Abstract][Full Text] [Related]